IUPAC/Chemical Name
5-Isothiazolecarboxylic acid, 4-amino-3-(3-(trifluoromethyl)phenyl)-
InChi Key
KVMCEGAWQYTFKC-UHFFFAOYSA-N
InChi Code
InChI=1S/C11H7F3N2O2S/c12-11(13,14)6-3-1-2-5(4-6)8-7(15)9(10(17)18)19-16-8/h1-4H,15H2,(H,17,18)
SMILES Code
O=C(C1=C(N)C(C2=CC=CC(C(F)(F)F)=C2)=NS1)O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
288.24
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Phillis JW, Sen S, Cao X. Amflutizole, a xanthine oxidase inhibitor, inhibits free radical generation in the ischemic/reperfused rat cerebral cortex. Neurosci Lett. 1994 Mar 14;169(1-2):188-90. PubMed PMID: 8047280.
2: O'Regan MH, Smith-Barbour M, Perkins LM, Cao X, Phillis JW. The effect of amflutizole, a xanthine oxidase inhibitor, on ischemia-evoked purine release and free radical formation in the rat cerebral cortex. Neuropharmacology. 1994 Oct;33(10):1197-201. PubMed PMID: 7862255.
3: Wortmann RL, Ridolfo AS, Lightfoot RW Jr, Fox IH. Antihyperuricemic properties of amflutizole in gout. J Rheumatol. 1985 Jun;12(3):540-3. PubMed PMID: 3900392.
4: Werns SW, Grum CM, Ventura A, Hahn RA, Ho PP, Towner RD, Fantone JC, Schork MA, Lucchesi BR. Xanthine oxidase inhibition does not limit canine infarct size. Circulation. 1991 Mar;83(3):995-1005. PubMed PMID: 1999047.
5: Millar AD, Rampton DS, Chander CL, Claxson AW, Blades S, Coumbe A, Panetta J, Morris CJ, Blake DR. Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. Gut. 1996 Sep;39(3):407-15. PubMed PMID: 8949646; PubMed Central PMCID: PMC1383348.
6: Manning A, Bernier M, Crome R, Little S, Hearse D. Reperfusion-induced arrhythmias: a study of the role of xanthine oxidase-derived free radicals in the rat heart. J Mol Cell Cardiol. 1988 Jan;20(1):35-45. PubMed PMID: 3367377.
7: Sanders SA, Eisenthal R, Harrison R. NADH oxidase activity of human xanthine oxidoreductase--generation of superoxide anion. Eur J Biochem. 1997 May 1;245(3):541-8. PubMed PMID: 9182988.
8: Cazevieille C, Muller A, Meynier F, Dutrait N, Bonne C. Protection by prostaglandins from glutamate toxicity in cortical neurons. Neurochem Int. 1994 Apr;24(4):395-8. PubMed PMID: 7914788.
9: Singh D, Nazhat NB, Fairburn K, Sahinoglu T, Blake DR, Jones P. Electron spin resonance spectroscopic demonstration of the generation of reactive oxygen species by diseased human synovial tissue following ex vivo hypoxia-reoxygenation. Ann Rheum Dis. 1995 Feb;54(2):94-9. PubMed PMID: 7702413; PubMed Central PMCID: PMC1005529.
